Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E.
Virgili G, et al. Among authors: parravano m.
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
Cochrane Database Syst Rev. 2017.
PMID: 28639415
Free PMC article.
Updated.
Review.
On average people receiving ranibizumab had worse VA at one year (MD 0.08 logMAR units, 95% CI 0.05 to 0.11), moderate-certainty evidence; and higher CRT (MD 39 m, 95% CI 2 m to 76 m; low-certainty evidence). Ranibizumab and bevacizumab were comparable with r …
On average people receiving ranibizumab had worse VA at one year (MD 0.08 logMAR units, 95% CI 0.05 to 0.11), moderate-certainty evidence; a …